United Arab Emirates Ministry of Health and Prevention Approves Biomerica's Fortel® Kidney Disease Test for Early Detection of Kidney Damage
IRVINE, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced diagnostic solutions, announced that its Fortel® Kidney Disease (Microalbumin) Test has been approved for sale by the United Arab Emirates (UAE) Ministry of Health and Prevention. This key regulatory milestone enables Biomerica to offer its innovative test across the UAE, a region facing a high burden of chronic kidney disease (CKD).
The Fortel® Kidney Disease Test is a rapid, easy-to-use diagnostic tool that provides accurate results in 10 minutes using a urine sample. By detecting low levels of microalbumin in urine (a critical early marker), the test can enable the early detection of kidney disease. Individuals with diabetes, hypertension, obesity and those over the age of 65 are at significantly increased risk for developing chronic kidney disease (CKD) and should be tested frequently. CKD is a worldwide public health problem that is highly underrecognized and more than 80% of at-risk patients are not diagnosed. Kidney disease enhances the risk of major non-communicable diseases including ischemic heart disease, stroke, cancer, etc. By 2040, CKD is projected to be the 5th highest cause of years of life lost globally.
Early detection of CKD allows for timely intervention that can slow or prevent progression to end-stage renal disease, requiring dialysis or kidney transplantation. In addition to reducing morbidity and mortality, early diagnosis can also lower the substantial economic burden associated with disease progression.
Diabetes and Hypertension: Two Major Risk Factors in the UAE
In the UAE, diabetes and hypertension are two of the most significant risk factors for chronic kidney disease (CKD). According to the International Diabetes Federation, over 12% of adults in the UAE live with diabetes, while regional studies estimate that 29% to 35% of the population have hypertension. Both conditions are leading contributors to CKD and often go undiagnosed until significant kidney damage has occurred. CKD is often referred to as a 'silent disease' because it typically shows few or no symptoms until it reaches an advanced and potentially irreversible stage. This makes early detection especially important.
'The Fortel® Kidney Disease Test addresses a critical need in preventative healthcare by allowing the possible detection of kidney disease before symptoms appear,' said Zack Irani, CEO of Biomerica. 'With the high prevalence of diabetes and hypertension in the UAE, this approval supports our mission to bring life-saving diagnostic tools to communities where they are most needed.'
Supporting Healthcare Access in the Middle East
This approval builds on Biomerica's growing presence in the Middle East, following the regional success of its EZ Detect™ Colon Disease Test and other innovative diagnostic products. The Company has established partnerships with leading distributors and healthcare providers in the UAE to allow the Fortel® Kidney Disease Test to be available across the country.
A Commitment to Early Detection and Better Outcomes
Biomerica remains dedicated to expanding access to cost-effective, high-quality diagnostics that empower patients and healthcare professionals. The Fortel® Kidney Disease Test is part of a broader portfolio of solutions designed to improve patient outcomes through early detection and personalized care.
About Biomerica (NASDAQ: BMRA )
Biomerica, Inc. (www.biomerica.com) is a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (in home and in physicians' offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. The Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica primarily focuses on gastrointestinal and inflammatory diseases where the Company has multiple diagnostic and therapeutic products in development.
The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made or to be made by Biomerica) contains statements that are forward-looking, such as statements relating to the Company's current and future sales, revenues, overhead, expenses, cost of goods, operations and earnings, efficacy of the Company's products and tests including the Fortel® Kidney Disease Test, FDA and/or international regulatory authorization for the Company's products to be marketed and sold, including the Fortel® Kidney Disease Test, and the Company's other current and future products, the possible expansion in to other markets, uniqueness of the Company's products, accuracy of the Company's tests and products, pricing of the Company's test kits, domestic and/or international market adoption and acceptance and demand for the Company's products including the Fortel® Kidney Disease Test, future use of the Company's products by physicians to treat their patients, potential revenues from the sale of current or future products. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results, in the future, including, without limitation: earnings and other financial results; results of studies testing the efficacy of the Company's inFoods tests and other products; regulatory approvals necessary prior to commercialization of the Company's products; availability of the Company's test kits and other products; capacity, shipping logistics, resource and other constraints on our suppliers; dependence on our third party manufacturers; dependence on international shipping carriers; governmental import/export regulations; demand for our various tests and other products; competition from other similar products and from competitors that have significantly more financial and other resources available to them; governmental virus control regulations that make it difficult or impossible for the company to maintain current operations; regulatory compliance and oversite, and the Company's ability to obtain patent protection on any aspects of its diagnostic or therapeutic technologies. Accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of Biomerica. Additionally, potential risks and uncertainties include, among others, fluctuations in the Company's operating results due to its business model and expansion plans, downturns in international and or national economies, the Company's ability to raise additional capital, the competitive environment in which the Company will be competing, and the Company's dependence on strategic relationships. The Company is under no obligation to update any forward-looking statements after the date of this release.
Corporate Contact:
Zack Irani | CEO
p. 949.645.2111
www.biomerica.com
Source: Biomerica
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
36 minutes ago
- Yahoo
PCR (qPCR, dPCR, Singleplex, Multiplex) Market Research Report 2025-2030 with Situation Analysis, Executives and Marketing Guide, & Investment Analysts and Management Consultants Guide
Explore the evolving PCR technology landscape with our comprehensive report. Discover market trends, including Singleplex and Multiplex testing, and the impact of digital PCR. Uncover investment opportunities in Point of Care Testing and Molecular Diagnostics. Gain insights with five-year forecasts and expert analysis. Dublin, June 12, 2025 (GLOBE NEWSWIRE) -- The "PCR Markets: Forecasts for qPCR, dPCR, Singleplex & Multiplex Markets and by Application, Product and Place Forecasting and Analysis" has been added to offering. This report provides comprehensive insights into how this convergence will shape future market dynamics, presenting critical information for industry stakeholders. The global landscape of disease diagnosis is undergoing a significant transformation, with PCR technology at its forefront. While the pandemic elevated PCR to a dominant position, ushering in a digital revolution within the sector, new markets and technologies are now emerging that may redefine diagnostics. This transition presents both opportunities and challenges for stakeholders. A newly released report offers an in-depth analysis of the market, featuring a five-year forecast that is uniquely segmented into Singleplex and Multiplex testing markets. PCR, which has showcased remarkable adaptability, gained widespread recognition as an essential tool in diagnostics. The advent of digital PCR further promises to enhance its efficacy, offering reduced costs and improved patient outcomes. Moreover, digital PCR stands as a powerful contender in combating Anti Microbial Resistance. For professionals seeking to leverage this data, the report is an indispensable resource that can transform executives into industry experts. It enables informed investment decisions and accurate company valuations, backed by the most current data available. With its detailed five-year market forecasts, the report equips organizations with the tools needed to strategically navigate this evolving landscape. In a market driven by innovation, understanding the nuances of these emerging technologies and their implications is crucial. This report encapsulates the trends, challenges, and opportunities that define the future of PCR technologies and diagnostics. Stay ahead of the curve by accessing the latest findings that will keep PCR at the core of disease detection and management globally. Discover how emerging diagnostics technology and market innovations are reshaping the competitive landscape. Access the full report today to explore untapped potential and prepare for the future of healthcare. Key Topics Covered: 1 Market Guides1.1 Situation Analysis1.2 Guide for Executives and Marketing Staff1.3 Guide for Investment Analysts and Management Consultants 2 Introduction and Market Definition2.1 What are PCR Technologies?2.2 PCR and Syndromic Testing2.3 Market Definition2.4 Methodology2.5 Perspective: Healthcare and the IVD Industry2.5.1 Global Healthcare Spending2.5.2 Spending on Diagnostics2.5.3 Important Role of Insurance for Diagnostics 3 PCR - Guide to PCR Technologies3.1 Concepts3.1.1 Method3.2 Applications3.2.1 Finding Specific DNA3.2.2 Measuring DNA3.2.3 Medical and Diagnostic Applications3.2.3.1 Carrier, prenatal and tissue typing3.2.3.2 Cancer Diagnosis and Management3.2.3.3 Infectious Disease - New Levels of Accuracy and Sensitivity3.2.3.4 Forensic Applications3.2.3.5 Science and Research3.3 PCR - Advantages and Disadvantages3.4 Different Types of PCR3.4.1 Simple Changes3.4.1.1 Multiplex-PCR3.4.1.2 VNTR PCR3.4.1.3 Asymmetric PCR3.4.1.4 Long PCR3.4.1.5 Nested PCR3.4.1.6 Quantitative PCR3.4.1.7 Hot-start PCR3.4.1.8 Touchdown PCR3.4.1.9 Assembly PCR3.4.1.10 Colony PCR3.4.1.11 Suicide PCR3.4.1.12 Cold PCR3.4.2 Digital PCR3.4.2.1 Droplet Digital PCR3.4.2.2 Comparison between dPCR and Real-Time PCR (qPCR)3.4.2.3 Digital PCR in Use3.4.2.4 Digital PCR Commercial History3.4.3 Isothermal PCR 4 Industry Overview4.1 Players in a Dynamic Market4.1.1 Academic Research Lab4.1.2 Diagnostic Test Developer4.1.3 Instrumentation Supplier4.1.4 Chemical/Reagent Supplier4.1.5 Pathology Supplier4.1.6 Independent Clinical Laboratory4.1.7 Public National/regional Laboratory4.1.8 Hospital Laboratory4.1.9 Physicians Office Lab (POLS)4.1.10 Audit Body4.1.11 Certification Body 5 Market Trends5.1 Factors Driving Growth5.1.1 A New Standard5.1.2 Down the Curve We Go5.1.3 Multiplexing5.1.4 Syndromic Diagnostics Looks Unstoppable5.1.5 The Genetic Blizzard5.2 Factors Limiting Growth5.2.1 The Cost Curve5.2.2 The Other Guys5.2.3 Systemic Roadblocks5.3 Diagnostic Technology Development5.3.1 The Instrumentation Curve5.3.2 Shifting Role of Diagnostics5.3.3 Diagnostics Moves Out of the Hospital5.3.4 Disruption Looms5.3.5 The Next Five Years 6 PCR Recent Developments6.1 Recent Developments - Importance and How to Use This Section6.1.1 Importance of These Developments6.1.2 How to Use This Section6.2 Seegene, Microsoft Collaborate for MDx Development6.3 QuidelOrtho Expanding Savanna Test Menu6.4 Binx Health Refocuses on POC STI Testing6.5 Qiagen, Myriad Genetics Partner to Develop Cancer Dx6.6 VedaBio Detecting Nucleic Acid With CRISPR6.7 Evvy Launches Add-on STI Screen6.8 ChromaCode Shifts to Oncology with dPCR Lung Cancer Test6.9 Multiplex Meningitis/Encephalitis Panel Market Expanding6.10 Sensible Dx to Launch 10-Minute POC PCR System6.11 ReadyGo Dx Plans to Make MDx Testing Easy6.12 Transformative Biotech Acquires Summit Biolabs' PCR Tech6.13 Visby Medical POC STI Multiplex Test Cleared6.14 Sherlock Biosciences Buys Sense Biodetection6.15 Agilent, Qiagen Nab FDA Approvals for Lung Cancer Treatment CDx6.16 HealthTrackRx Investing in Rapid Turnaround Times6.17 LEX Dx Developing Ultra-Fast Low-Cost PCR6.18 Next-Gen Dx Technologies Face Uncertain Future6.19 Rover Dx Developing All-Optical Rapid POC qPCR Platform6.20 ProtonDx Plans Rapid Molecular Dx Instrument6.21 Innova Medical Group Licenses MDx Tech6.22 MicroGEM to Grow Market for 30-Minute RT-PCR System6.23 Precipio Receives CE-IVD Mark for Cancer Panels6.24 Siemens Healthineers to Develop Next-Gen MDx Platform6.25 New York State Approves Enzo Biochem HPV Molecular Test6.26 Grip Molecular Developing Biosensor Panel to Detect Respiratory Infections6.27 Co-Diagnostics Seeks EUA for At-Home PCR Diagnostic System6.28 Chelex-Based Protocol to Reduce Cost, Time for PCR Testing6.29 Finnish Firms to Form Point-of-Care Testing Firm6.30 Visby Medical Scales Up Handheld PCR Test for STIs6.31 DnaNudge Raises $60M6.32 Roche Reports Diagnostics Revenue Up 51 Percent6.33 BforCure Preparing Multiple ID Panels for PoC qPCR Platform6.34 Enzo Biochem, CLX Health Partner for C19 Testing for Travel6.35 Bio Molecular Systems Gets Approval for Portable PCR Cycler6.36 Roche Acquires GenMark6.37 Handheld qPCR Devices Close to Commercialization6.38 Nuclein Closes $14M in Funding6.39 WuXi Diagnostics Closes $150M Series B Financing Round6.40 Visby Medical to develop rapid Flu-COVID PCR test6.41 Thermo Fisher to Acquire Mesa Biotech 7 Profiles of Key PCR Companies7.1 Abbott Laboratories7.2 Accelerate Diagnostics7.3 Ador Diagnostics7.4 ADT Biotech7.5 Agilent7.6 Akonni Biosystems7.7 Altona Diagnostics7.8 Alveo Technologies7.9 Amoy Diagnostics Co., Ltd.7.10 Anatolia Geneworks7.11 Applied BioCode7.12 Applied DNA Sciences7.13 Aurora Biomed7.14 Aus Diagnostics7.15 AVIVA Systems Biology7.16 Beckman Coulter Diagnostics (Danaher)7.17 Becton, Dickinson and Company7.18 Binx Health7.19 Biocartis7.20 bioMerieux Diagnostics7.21 Bioneer Corporation7.22 Bio-Rad Laboratories, Inc7.23 Bosch Healthcare Solutions GmbH7.24 Bruker7.25 Caris Molecular Diagnostics7.26 Cepheid (Danaher)7.27 Credo Diagnostics Biomedical7.28 CTK Biotech7.29 Cue Health7.30 Curetis (OpGen)7.31 Diagenode Diagnostics (Hologic)7.32 Diasorin S.p.A.7.33 Eiken Chemical7.34 Enzo Biochem7.35 Eurofins Scientific7.36 Fluxergy7.37 Fujirebio7.38 Genetic Signatures7.39 GenMark Dx (Roche)7.40 Greiner Bio-One7.41 Hologic7.42 Immunexpress7.43 Inflammatix7.44 Invetech7.45 J&J Innovative Medicine7.46 Karius7.47 LumiraDx7.48 Maxim Biomedical7.49 Meridian Bioscience7.50 Millipore Sigma7.51 Molbio Diagnostics7.52 Nanomix7.53 NGeneBio7.54 Novacyt7.55 Nuclein7.56 Operon7.57 Panagene7.58 Precipio7.59 Primerdesign (Novacyt)7.60 Promega7.61 Prominex7.62 Qiagen7.63 QuantuMDx7.64 QuidelOrtho7.65 Randox Toxicology7.66 R-Biopharm AG7.67 Revvity7.68 Roche Diagnostics7.69 Scope Fluidics7.70 SD Biosensor7.71 Seegene7.72 Siemens Healthineers7.73 SkylineDx7.74 Sona Nanotech7.75 SpeeDx7.76 Standard BioTools7.77 Stilla Technologies7.78 Streamline Scientific7.79 T2 Biosystems7.80 Thermo Fisher Scientific7.81 Uniogen7.82 Vela Diagnostics7.83 Veramarx7.84 Veredus Laboratories7.85 Vircell7.86 Visby Medical7.87 XCR Diagnostics7.88 YD Diagnostics7.89 Zhejiang Orient Gene Biotech 8 The Global PCR Markets8.1 PCR - Global Market Overview by Country8.2 Global Market by Application - Overview8.3 Global Market by Technology - Overview8.4 Global Market by Product - Overview8.5 Global Market by Place - Overview 9 Global PCR Markets - By Application9.1 PCR Clinical Multiplex9.2 PCR Clinical Singleplex9.3 PCR Research 10 Global PCR Markets - By Technology10.1 qPCR10.2 dPCR 11 Global PCR Markets - By Product11.1 PCR Instruments11.2 PCR Nucleic Acid Extraction11.3 PCR Consumables11.4 PCR Services 12 Global PCR Markets - By Place12.1 PCR Clinical Laboratory12.2 PCR Point of Care12.3 PCR Commercial12.4 PCR Pharmaceutical 13 Appendices13.1 Growth of Approved IVD Test Menu13.2 Growth of Approved Average IVD Test Fee13.3 The Most Used IVD Assays13.4 The Highest Grossing Assays13.5 Laboratory Fees Schedule For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Yahoo
an hour ago
- Yahoo
Gavin Gassen, M.D. Brings His Expertise to ENT and Allergy Associates' Poughkeepsie Office
Dr. Gassen will see both adult and pediatric patients at ENTA's office at 21 Reade Place, Suite 3200, Poughkeepsie, NY, beginning November 1, 2025. ENTA Otolaryngologist and Head and Neck Surgeon Gavin Gassen, M.D. Tarrytown, New York, June 12, 2025 (GLOBE NEWSWIRE) -- ENT and Allergy Associates, LLP (ENTA), the largest ear, nose, throat, allergy, and audiology practice in the country, is proud to welcome Gavin M. Gassen, M.D., a board-certified Otolaryngologist and Head and Neck Surgeon, to its team of specialists in Poughkeepsie, NY, beginning November 1, 2025. Dr. Gassen will see both adult and pediatric patients at ENTA's office at 21 Reade Place, Suite 3200, Poughkeepsie, NY. Dr. Gassen brings with him a diverse clinical experience few physicians can match—spanning academic medicine, humanitarian missions, and over a decade of decorated service in the U.S. Navy Medical Corps. Dr. Gassen most recently practiced at Plessen Ear, Nose & Throat in St. Croix, U.S.V.I., while also serving as Adjunct Assistant Professor of Otolaryngology at Tulane University School of Medicine. A New Orleans native, he completed his undergraduate and medical degrees at Tulane, followed by intensive surgical training at Charity Hospital, Memorial Sloan-Kettering Cancer Center, and the University of Maryland. During his military service, Dr. Gassen earned the rank of Commander and served as a Naval Flight Surgeon during Operation Iraqi Freedom. He was awarded the Navy/Marine Corps Commendation Medal among other honors, for excellence in patient care and operational leadership. Beyond the clinic, Dr. Gassen has also led medical missions delivering head and neck surgical care to underserved communities and has been published in several peer-reviewed journals. He holds memberships in the American Academy of Otolaryngology–Head and Neck Surgery, American Academy of Otolaryngic Allergy, American Rhinologic Society, the American Academy of Sleep Medicine and The Society of U.S. Naval Flight Surgeons. In the Poughkeepsie office, Dr. Gassen will join Otolaryngologists Ryan Borress, M.D.; Jason Cohen, M.D., F.A.C.S; Rami Payman, M.D., Hector Rodriguez, M.D.; Mark Very, M.D.; and Allergist/Immunologist Michael Hugh, M.D. 'Dr. Gassen's background is as impressive as it is unique,' said Steven Gold, M.D., Vice President and Chair of the ENTA Recruitment Committee. 'He's served with distinction in the U.S. Navy, trained at world-renowned institutions, and delivered care across academic, private, and international humanitarian settings. That kind of experience translates into a physician who brings both clinical excellence and deep compassion to his patients. I have no doubt that his addition to our Poughkeepsie team will result in an immediate and meaningful benefit to the community. We are truly proud to welcome him to ENTA.' To learn more about ENTA, find a local office or book an appointment, visit or call 1-855-ENTA-DOC. About ENT and Allergy Associates, LLP: ENT and Allergy Associates, LLP (ENTA) is the largest ENT, Allergy, and Audiology practice in the country, with over 450 clinicians who now practice in over 60 clinical locations throughout New York, New Jersey, and Pennsylvania. Each ENTA clinical office is comprised of world-class physicians who are specialists and sub-specialists in their respective fields, providing the highest level of expertise and care. With a wide range of services including Adult and Pediatric ENT and Allergy, Voice and Swallowing, Advanced Sinus and Skull Base Surgery, Facial Plastics and Reconstructive Surgery, Treatment of Disorders of the Inner Ear and Dizziness, Asthma-related services, Diagnostic Audiology, Hearing Aid Dispensing, Sleep and CT Services, ENTA Is able to meet the needs of patients of all ages. ENTA is also affiliated with some of the most prestigious medical institutions in the world, including The Mount Sinai Health System, Montefiore Medical Center, Northwell Health and Cooperman Barnabas Medical Center. Each year ENTA physicians are voted 'Top Doctor' by Castle Connolly, a true testament to the exceptional care and service they provide to their patients. Attachment ENTA Otolaryngologist and Head and Neck Surgeon Gavin Gassen, M.D. CONTACT: Jason Campbell ENT and Allergy Associates, LLP 914-984-2531 Jcampbell@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Inter Scientific Supports Jupiter Research in Achieving EU Certification for First Handheld Liquid Inhalation Device
LIVERPOOL, United Kingdom, June 12, 2025 (GLOBE NEWSWIRE) -- Inter Scientific is pleased to announce its role, in collaboration with Jupiter Research LLC, as the regulatory partner for the first handheld Liquid Inhalation Device to receive regulatory approval under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone marks a significant step forward in the medical device landscape and opens the door for wider global access to innovative inhalation technologies. Jupiter Research, a pioneering company in the liquid vaporizer space, identified early in its development journey the importance of an expert regulatory partner. After an initial review process, Jupiter selected Inter Scientific based on its ability to meet the demands and complexity of the EU MDR. This decision proved instrumental in Jupiter's successful regulatory approval. 'Jupiter recognised very early in the process that external support would be beneficial,' stated Jupiter's Senior Director of Engineering, Jordan Walker. 'We chose Inter Scientific based on their expertise and felt they were efficient and professional throughout the contract, helping us achieve our goals and gain regulatory approval.' Walker continued, 'Inter Scientific provided expertise in the creation of the device's comprehensive Technical File, development of the required Quality Management System documentation, and delivery of tailored educational services to Jupiter's internal teams. This approach enabled a streamlined path to regulatory compliance.' David Lawson, Executive Director at Inter Scientific, commented:'At every stage of this rigorous certification process, Inter Scientific maintained a customer-focused approach, working closely with the Jupiter team and delivering timely, professional, and accurate support. We're proud to be recognised as a key contributor to this success and look forward to building on this achievement through continued collaboration on future regulatory initiatives.' Inter Scientific's in-depth understanding of the regulatory framework helped Jupiter design the device in line with medical classification requirements, prepare the necessary documentation, and respond effectively to regulatory feedback, which resulted in the successful approval of a first of its kind device now poised to make its mark in global healthcare. About Inter ScientificInter Scientific is an independent, accredited contract research organisation (CRO) providing regulatory science, product testing, and compliance services across highly regulated industries. With over a decade of experience, we support clients in the medical device, pharmaceutical, nicotine product, cosmetic, and novel food sectors. Inter Scientific operates to the highest quality standards, holding ISO/IEC 17025 accreditation and operating in accordance with Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP). Our expert team delivers scientifically robust, regulatory-ready data and strategic guidance to help clients navigate complex global regulations and bring compliant products to market with confidence. Inter Scientific Media Contact Razieh Alipour Digital Marketing Content in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
